Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby, które świadomie zgodziły się na udział i będą przestrzegać zaleceń lekarza.
- •Osoby w wieku od 18 do 70 lat.
- •Pacjenci z konkretnym typem chłoniaka nieziarniczego z komórek B (zweryfikowanym w badaniach), który powrócił lub jest oporny na leczenie.
- •Pacjenci, którzy przeszli już co najmniej dwa różne rodzaje leczenia lub przeszczep własnych komórek macierzystych.
- •Pacjenci z aktywną chorobą (chłoniakiem) w momencie rozpoczęcia badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
The Third Xiangya Hospital of Central South University
Changsha, China
The First Affiliated Hospital of Soochow University
Suzhou, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Trial contact
Xiaoyan Lou, PhD
Liqing Kang, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.